Catalyst: Systems chemistry links reactions to molecular function
- PMID: 40673223
- PMCID: PMC12266709
- DOI: 10.1016/j.chempr.2024.06.009
Catalyst: Systems chemistry links reactions to molecular function
Abstract
Andrew McGrath completed his PhD studies at the University of Michigan with Tim Cernak, studying amine-acid coupling reactions and their application in medicinal chemistry. Andrew was an undergraduate of the University of Colorado at Colorado Springs and is currently a postdoctoral researcher at Merck & Co., Inc. in Rahway, NJ. Haiyan Huang is currently a postdoctoral fellow in the Cernak Lab at the University of Michigan, where she studies amine-acid coupling reactions. She earned her BSc from Sun Yat-sen University and her PhD studying total synthesis at McGill University under the supervision of Prof. Lumb. Christopher O. Audu is currently a chief resident in vascular surgery at the University of Michigan. He studied at Purdue (BSc) and Dartmouth (MD and PhD) and performed postdoctoral research with Drs. Cernak and Gallagher at the University of Michigan. He will begin an assistant professorship of vascular surgery and chemical research at the University of Utah in the fall of 2024. Tim Cernak is an associate professor of medicinal chemistry at the University of Michigan, exploring the role of data science in chemistry and medicine in biodiversity conservation. Prior to working at the University of Michigan, he worked at Merck & Co., Inc. He is a co-founder of Iambic Therapeutics.
Conflict of interest statement
Research in the Cernak Lab has been supported by MilliporeSigma, Janssen, Relay, Merck, SPT Labtech, the National Defense Medical Center, the Shanghai University of Traditional Chinese Medicine, and Entos, Inc. Tim Cernak has consulted for the University of Dundee Drug Discovery Unit, Scorpion Therapeutics, Relay Therapeutics, Amgen, Genentech, Janssen, Pfizer, Vertex, MilliporeSigma, the US Food & Drug Administration, Gilead, AbbVie, Corteva, Syngenta, Firmenich, Biogen, Bayer, UCB Biopharma, the National Taiwan University, AstraZeneca, Grunenthal, and Iambic Therapeutics (previously known as Entos, Inc.). He holds equity in Scorpion Therapeutics and is a co-founder of and equity holder in Iambic Therapeutics.
Figures
References
-
- Weinberg GM (2001). An Introduction to General Systems Thinking (Dorset House).
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous